In the evolving landscape of pharmaceutical manufacturing, implementing a robust Quality by Design (QbD) strategy is not just best practice — it’s regulatory expectation. For small molecule APIs, especially those outsourced to Contract Development and Manufacturing Organizations (CDMOs), the QbD framework is central to ensuring product quality, minimizing regulatory risk, and securing market approval.

What Is a QbD Strategy in Small Molecule API Development?

At its core, QbD is a scientific, risk-based, and proactive approach to pharmaceutical development. Rather than treating quality as a checkbox at the end of development, QbD integrates it throughout the design and scale-up of a drug substance.

As defined by ICH Q8(R2), QbD involves identifying:

• The Quality Target Product Profile (QTPP)
• Critical Quality Attributes (CQAs)
• Critical Process Parameters (CPPs)
• Conducting risk assessments and design space exploration

By establishing this foundation early, drug sponsors can reduce variability, anticipate failure modes, and respond to regulatory scrutiny with confidence.

Why CDMO Selection Impacts Regulatory Risk

Partnering with a CDMO can accelerate time to market—but it also introduces significant risk if QbD principles aren’t harmonized. According to a 2023 report by Pharma Manufacturing, over 40% of regulatory delays for outsourced APIs were linked to inadequate process understanding or incomplete risk documentation at the CDMO level.

Sponsors often assume their CDMO has QbD expertise baked into operations. Unfortunately, this is not always the case. If QbD is poorly implemented—or misaligned between sponsor and manufacturer—it can result in:

• Inconsistent batch quality
• Delayed tech transfers
• FDA Form 483 observations
• Or even Complete Response Letters (CRLs)

To learn more about evaluating partners, visit our CDMO selection guide.

Common Gaps in QbD Execution Across CDMOs

Even top-tier CDMOs can struggle with:

• Incomplete Design Space justifications
• Limited use of risk-based process control strategies
• Minimal integration of real-time data into decision-making
• Disconnected documentation systems that hinder traceability

A 2022 BioPhorum Operations Group benchmark found that only 55% of CDMOs regularly updated their control strategies post-process validation, leaving sponsors exposed during regulatory inspections.

How to Build a Resilient QbD Framework With Your CDMO Partner

To mitigate these risks, sponsors should:

• Co-develop the QTPP and CQA framework early in the process
• Align on process analytical technologies (PAT) and data flows
• Establish joint governance committees with quality and regulatory representation
• Ensure QRM (Quality Risk Management) is not a paper exercise but operationally enforced

An effective QbD strategy with a CDMO is not one-directional. It’s a collaborative architecture, where both parties bring scientific and regulatory understanding to the table.

Regulatory Expectations: EMA, FDA, and ICH Perspectives

Regulators increasingly expect QbD as a standard—not a bonus. According to the EMA’s Reflection Paper on QbD, sponsors are encouraged to demonstrate a clear link between control strategy and process knowledge. Meanwhile, the FDA’s QbD initiative has evolved into broader expectations under modern CMC guidance.

Moreover, ICH Q9(R1) (revised in 2023) places even more emphasis on subjectivity reduction in risk assessments, which is particularly relevant when evaluating third-party CDMOs.

Risk Mitigation Strategies for API Scale-Up and Tech Transfer

During scale-up or site transfers, poorly defined QbD elements can derail timelines. Some mitigation tactics include:

• Running multivariate design of experiments (DoE) at pilot scale
• Implementing process robustness indices (e.g., CpK or PpK)
• Verifying equipment equivalency across sites
• Conducting mock inspections with regulatory affairs to preempt gaps

Tech transfer failures are among the most cited issues in CDMO collaborations. As noted in a 2024 McKinsey analysis, nearly 30% of delayed IND or NDA submissions were rooted in avoidable scale-up and documentation gaps.

Integrating Quality Risk Management (QRM) and QbD Principles

While QbD defines the roadmap, QRM guides the journey. QRM tools like FMEA, fault tree analysis, and hazard analysis are essential to prioritizing control strategies and ensuring process safety.

Yet many teams treat QbD and QRM as siloed efforts. The real power lies in their integration—designing processes with risk in mind, then validating them with real-world data across the development lifecycle.

Want to align your QbD strategy with regulatory best practices? Explore our regulatory risk advisory services.

Frequently Asked Questions: QbD, CDMOs, and Regulatory Risk

What is the difference between QbD and QRM in CDMO settings?

QbD is the overarching strategy to design quality into a process; QRM is the toolkit used to assess, prioritize, and control risks throughout development and manufacturing. Both are critical and complementary.

Can a CDMO take full ownership of the QbD process?

Not ideally. While CDMOs may generate process data and execute risk assessments, the sponsor remains accountable for overall regulatory strategy and must co-author key QbD elements for filing purposes.

How do regulators evaluate QbD compliance in API filings?

Regulators assess the alignment between process understanding, control strategy, and the filed documentation. Lack of design space rationale or unclear CPP/CQA links can trigger information requests or inspection findings.

What are common red flags in CDMO quality systems?

• Lack of QbD documentation
• Limited change control procedures
• Infrequent data trending
• Minimal training on risk-based manufacturing

Conclusion: Aligning QbD Strategy With the Right CDMO Is Non-Negotiable

The road from small molecule development to approval is paved with complexity. But by embedding a scientifically sound, regulator-aligned QbD strategy—and choosing a CDMO that can truly partner in that vision—you reduce risk, ensure compliance, and protect your launch timeline.

As seen across FDA inspections and EMA filings, QbD is no longer optional. It’s your competitive edge.